Twelve firms are battling to be appointed lead counsel in a putative securities class action accusing Iovance Biotherapeutics of causing its stock price to drop 44% in a single day by misrepresenting the anticipated demand for one of its cancer treatments.
In the competing motions filed Monday, some of the firms cited their history of securing large settlements on behalf of investors to sway U.S. District Judge Eumi K. Lee in San Jose. Others claimed their clients' sizable lo...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In